Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298727 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Ségolène Turquier und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Centre for Rare Pulmonary Diseases and Centre for Pulmonary Hypertension, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, Fr…. Hauptthemen laut MEDLINE: Cardiac Output, Hypertension, Pulmonary, Thermodilution. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiac output (CO) is one of the primary prognostic factors evaluated during the follow-up of patients treated for pulmonary hypertension (PH). It is recommended that it be measured using the thermodilution technique during right heart catheterization. The difficulty to perform iterative invasive measurements on the same individual led us to consider a non-invasive option. The aims of the present study were to assess the agreement between CO values obtained using bioreactance (Starling ™ SV) and thermodilution, and to evaluate the ability of the bioreactance monitor to detect patients whose CO decreased by more than 15% during follow-up and, accordingly, its usefulness for patient monitoring. A prospective cohort study evaluating the performance of the Starling ™ SV monitor was conducted in patients with clinically stable PH. Sixty patients referred for hemodynamic assessment were included. CO was measured using both the thermodilution technique and bioreactance during two follow-up visits. A total of 60 PH patients were included. All datasets were available at the baseline visit (V0) and 50 of them were usable during the follow-up visit (V1). Median [IQR] CO was 4.20 l/min [3.60–4.70] when assessed by bioreactance, and 5.30 l/min [4.57–6.20] by thermodilution (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Reference Centre for Rare Pulmonary Diseases and Centre for Pulmonary Hypertension, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France.
- Lung Physiology Unit, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France.
- Innovation Department, Health Economic Evaluation Service, Public Health Centre, Hospices Civils de Lyon, Lyon, France.
- Research on Healthcare Performance RESHAPE, INSERM U1290, Claude Bernard University, Lyon, France.
- Biostatistics and Bioinformatics Department, Public Health Centre, Hospices Civils de Lyon, Lyon, France.
- UMR754, INRAE, Claude Bernard University, Lyon, France.
ORCID-Profile: Ségolène Turquier, Laure Huot
Zitieren
APA
Turquier, S., Huot, L., Lamkhioued, M., Subtil, F., Traclet, J., Ahmad, K., Lestelle, F., Chauvelot, L., Cottin, V., & Mornex, J. F. (2024). Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension. PLOS ONE. https://doi.org/10.1371/journal.pone.0298727
Vancouver
Turquier S, Huot L, Lamkhioued M, Subtil F, Traclet J, Ahmad K, et al. Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension. PLOS ONE. 2024. doi:10.1371/journal.pone.0298727
BibTeX
@article{Turquier2024,
author = {Turquier, Ségolène and Huot, Laure and Lamkhioued, Medhi and Subtil, Fabien and Traclet, Julie and Ahmad, Kais and Lestelle, François and Chauvelot, Louis and Cottin, Vincent and Mornex, Jean-François},
title = {Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298727}
}
EUVIMED